7a5b: Difference between revisions
No edit summary |
No edit summary |
||
(One intermediate revision by the same user not shown) | |||
Line 3: | Line 3: | ||
<StructureSection load='7a5b' size='340' side='right'caption='[[7a5b]], [[Resolution|resolution]] 2.60Å' scene=''> | <StructureSection load='7a5b' size='340' side='right'caption='[[7a5b]], [[Resolution|resolution]] 2.60Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'> | <table><tr><td colspan='2'>Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=7A5B OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=7A5B FirstGlance]. <br> | ||
</td></tr><tr id=' | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.6Å</td></tr> | ||
<tr id=' | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=MFR:4-(4-METHOXY-1H-PYRROLO[2,3-B]PYRIDIN-3-YL)PYRIMIDIN-2-AMINE'>MFR</scene>, <scene name='pdbligand=PTR:O-PHOSPHOTYROSINE'>PTR</scene></td></tr> | ||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=7a5b FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=7a5b OCA], [https://pdbe.org/7a5b PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=7a5b RCSB], [https://www.ebi.ac.uk/pdbsum/7a5b PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=7a5b ProSAT]</span></td></tr> | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=7a5b FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=7a5b OCA], [https://pdbe.org/7a5b PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=7a5b RCSB], [https://www.ebi.ac.uk/pdbsum/7a5b PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=7a5b ProSAT]</span></td></tr> | ||
</table> | </table> | ||
<div style="background-color:#fffaf0;"> | <div style="background-color:#fffaf0;"> | ||
== Publication Abstract from PubMed == | == Publication Abstract from PubMed == | ||
Line 24: | Line 17: | ||
</div> | </div> | ||
<div class="pdbe-citations 7a5b" style="background-color:#fffaf0;"></div> | <div class="pdbe-citations 7a5b" style="background-color:#fffaf0;"></div> | ||
== References == | == References == | ||
<references/> | <references/> | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
[[Category: Large Structures]] | [[Category: Large Structures]] | ||
[[Category: Dokurno | [[Category: Dokurno P]] | ||
[[Category: Hubbard | [[Category: Hubbard RE]] | ||
[[Category: Surgenor | [[Category: Surgenor AE]] | ||
Latest revision as of 12:19, 9 October 2024
Structure of DYRK1A in complex with complex 10Structure of DYRK1A in complex with complex 10
Structural highlights
Publication Abstract from PubMedThe serine/threonine kinase DYRK1A has been implicated in regulation of a variety of cellular processes associated with cancer progression, including cell cycle control, DNA damage repair, protection from apoptosis, cell differentiation, and metastasis. In addition, elevated-level DYRK1A activity has been associated with increased severity of symptoms in Down's syndrome. A selective inhibitor of DYRK1A could therefore be of therapeutic benefit. We have used fragment and structure-based discovery methods to identify a highly selective, well-tolerated, brain-penetrant DYRK1A inhibitor which showed in vivo activity in a tumor model. The inhibitor provides a useful tool compound for further exploration of the effect of DYRK1A inhibition in models of disease. Fragment-Derived Selective Inhibitors of Dual-Specificity Kinases DYRK1A and DYRK1B.,Lee Walmsley D, Murray JB, Dokurno P, Massey AJ, Benwell K, Fiumana A, Foloppe N, Ray S, Smith J, Surgenor AE, Edmonds T, Demarles D, Burbridge M, Cruzalegui F, Kotschy A, Hubbard RE J Med Chem. 2021 Jun 18. doi: 10.1021/acs.jmedchem.1c00024. PMID:34143631[1] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. References
|
|